617 results on '"Grace, Rachael F."'
Search Results
2. The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia
3. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency
4. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines
5. Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial
6. Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol
7. Updates and advances in pyruvate kinase deficiency
8. An update on pediatric ITP: differentiating primary ITP, IPD, and PID
9. Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT).
10. Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency
11. Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiency
12. 2022 Review of the 2019 American Society of Hematology Guidelines on Immune Thrombocytopenia
13. Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology
14. What is in a name: defining pediatric refractory ITP
15. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
16. International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee
17. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency
18. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines
19. Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment
20. Comorbidities and complications in adult and paediatric patients with pyruvate kinase deficiency: Analysis from the Peak Registry
21. Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency
22. Comorbidities and complications in adult and paediatric patients with pyruvate kinase deficiency: Analysis from the Peak Registry.
23. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1
24. Management of pyruvate kinase deficiency in children and adults
25. Integrating circulating T follicular memory cells and autoantibody repertoires for characterization of autoimmune disorders
26. American Society of Hematology 2019 guidelines for immune thrombocytopenia
27. Pyruvate kinase activators for treatment of pyruvate kinase deficiency
28. Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review
29. Red Blood Cell Enzyme Disorders
30. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
31. P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL
32. P1479: COMORBIDITIES AND COMPLICATIONS IN ADULTS WITH PYRUVATE KINASE DEFICIENCY ACCORDING TO HEMOGLOBIN STRATA – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY
33. PB2619: THE IMPACT OF ITP-DIRECTED TREATMENT ON FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
34. P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL
35. PB2620: NIGHTTIME SYMPTOMS ARE ASSOCIATED WITH FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
36. P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
37. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia
38. HLA antibodies in fetal and neonatal alloimmune thrombocytopenia
39. The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry:rationale and study design
40. The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design
41. Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency
42. Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency
43. The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design
44. Early‐onset reduced bone mineral density in patients with pyruvate kinase deficiency
45. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP
46. Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura
47. Pediatric refractory immune thrombocytopenia: A systematic review
48. Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia
49. Utilization of an ITP quality improvement pathway improves adherence to management guidelines
50. Long-Term Risk of Developing Immune Thrombocytopenia and Hematologic Neoplasia in Adults with Persistent, Isolated Mild Thrombocytopenia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.